Discovery of lead natural products for developing pan-SARS-CoV-2 therapeutics

Jimena Pérez-Vargas,Tirosh Shapira,Ivan Villanueva,Siobhan Ennis,Guang Gao,Joshua De Guzman,Meng Wang,Aaleigha Chin,Diana Bautista-Sánchez,Olga Agafitei,Paul Levett,Xuping Xie,Genoveffa Nuzzo,Virayu Suthiphasilp,Achara Raksat,Pornphimol Meesakul,Isaraporn Polbuppha,Sarot Cheenpracha,Wuttichai Jaidee,Kwanjai Kanokmedhakul,Chavi Yenjai,Boonyanoot Chaiyosang,Helder Lopes Teles,Emiliano Manzo,Angelo Fontana,Richard Leduc,Pierre-Luc Boudreault,Surat Laphookhieo,Somdej Kanokmedhakul,Ian Tietjen,Artem Cherkasov,Mel Krajden,Ivan Robert Nabi,Masahiro Niikura,Pei-Yong Shi,François Jean,Andrea D. Olmstead,Connor A.H. Thompson,David E. Williams,Vitor F. Freire,Jairo I. Quintana-Bulla,Darlon I. Bernardi,Juliana R. Gubiani,Roberto G.S. Berlinck,Raymond J. Andersen

DOI: https://doi.org/10.1016/j.antiviral.2022.105484

IF: 7.6

2023-01-01

Antiviral Research

Abstract:The COVID-19 pandemic, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), remains a global public health crisis. The reduced efficacy of therapeutic monoclonal antibodies against emerging SARS-CoV-2 variants of concern (VOCs), such as omicron BA.5 subvariants, has underlined the need to explore a novel spectrum of antivirals that are effective against existing and evolving SARS-CoV-2 VOCs. To address the need for novel therapeutic options, we applied cell-based high-content screening to a library of natural products (NPs) obtained from plants, fungi, bacteria, and marine sponges, which represent a considerable diversity of chemical scaffolds. The antiviral effect of 373 NPs was evaluated using the mNeonGreen (mNG) reporter SARS-CoV-2 virus in a lung epithelial cell line (Calu-3). The screening identified 26 NPs with half-maximal effective concentrations (EC₅₀) below 50 μM against mNG-SARS-CoV-2; 16 of these had EC₅₀ values below 10 μM and three NPs (holyrine A, alotaketal C, and bafilomycin D) had EC₅₀ values in the nanomolar range. We demonstrated the pan-SARS-CoV-2 activity of these three lead antivirals against SARS-CoV-2 highly transmissible Omicron subvariants (BA.5, BA.2 and BA.1) and highly pathogenic Delta VOCs in human Calu-3 lung cells. Notably, holyrine A, alotaketal C, and bafilomycin D, are potent nanomolar inhibitors of SARS-CoV-2 Omicron subvariants BA.5 and BA.2. The pan-SARS-CoV-2 activity of alotaketal C [protein kinase C (PKC) activator] and bafilomycin D (V-ATPase inhibitor) suggest that these two NPs are acting as host-directed antivirals (HDAs). Future research should explore whether PKC regulation impacts human susceptibility to and the severity of SARS-CoV-2 infection, and it should confirm the important role of human V-ATPase in the VOC lifecycle. Interestingly, we observed a synergistic action of bafilomycin D and N-0385 (a highly potent inhibitor of human TMPRSS2 protease) against Omicron subvariant BA.2 in human Calu-3 lung cells, which suggests that these two highly potent HDAs are targeting two different mechanisms of SARS-CoV-2 entry. Overall, our study provides insight into the potential of NPs with highly diverse chemical structures as valuable inspirational starting points for developing pan-SARS-CoV-2 therapeutics and for unravelling potential host factors and pathways regulating SARS-CoV-2 VOC infection including emerging omicron BA.5 subvariants.

pharmacology & pharmacy,virology